Perception of prescription drug monitoring programs as a prevention tool in primary medical care

Amie J. Goodin, Joshua D. Brown, Chris Delcher, Patricia R. Freeman, Jeffery Talbert, Stephen G. Henry, Dikea Roussos-Ross

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.

Original languageEnglish
Pages (from-to)1306-1308
Number of pages3
JournalResearch in Social and Administrative Pharmacy
Issue number9
StatePublished - Sep 2020

Bibliographical note

Funding Information:
This project was not funded directly, but secondary analysis was conducted using survey data acquired with permission from: the University of Kentucky Institute for Pharmaceutical Outcomes and Policy, House Bill 1 Impact Evaluation of Kentucky's Prescription Drug Monitoring Program (Harold Rogers Grant #: 2011-PM-BX-2007, awarded by Bureau of Justice Assistance); the University of Florida (Harold Rogers Grant #: 2013-PM-BX-0010, awarded by Bureau of Justice Assistance); The California Department of Justice (Harold Rogers Grant #2015-PM-BX-K001, awarded by Bureau of Justice Assistance), and the California Department of Public Health (Prevention for States grant #1U17CE002747, awarded by the CDC).

Funding Information:
The authors wish to thank and acknowledge the research teams from the University of Kentucky (SuZanne Troske), the University of Florida (Yanning Wang, Bruce A. Goldberger), and the California Department of Public Health (John Pugliese), for sharing survey data collected during their respective evaluations of each state's Prescription Drug Monitoring Program.

Publisher Copyright:
© 2019 Elsevier Inc.


  • Controlled substance use in pregnancy
  • Neonatal abstinence syndrome
  • Opioid analgesics
  • Prescription drug monitoring programs

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science


Dive into the research topics of 'Perception of prescription drug monitoring programs as a prevention tool in primary medical care'. Together they form a unique fingerprint.

Cite this